JN403

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525890

CAS#: 942606-12-4

Description: JN403 is a selective nicotinic acetylcholine receptor alpha7 agonist.

Chemical Structure

img
JN403
CAS# 942606-12-4
Instruction

Theoretical Analysis

MedKoo Cat#: 525890
Name: JN403
CAS#: 942606-12-4
Chemical Formula: C16H21FN2O2
Exact Mass: 292.16
Molecular Weight: 292.354
Elemental Analysis: C, 65.73; H, 7.24; F, 6.50; N, 9.58; O, 10.94

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: JN403

IUPAC/Chemical Name: (1-Aza-bicyclo[2.2.2]oct-3(S)--yl)-carbamic acid 1(S)-(2-fluoro-phenyl)-ethyl ester

InChi Key: CKBCVTOFGWWVMT-OAHLLOKOSA-N

InChi Code: InChI=1S/C16H21FN2O2/c17-14-4-2-1-3-12(14)7-10-21-16(20)18-15-11-19-8-5-13(15)6-9-19/h1-4,13,15H,5-11H2,(H,18,20)/t15-/m1/s1

SMILES Code: O=C(OCCC1=CC=CC=C1F)N[C@@H]2C[N@]3CCC2CC3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 292.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lilja AM, Malmsten L, Röjdner J, Voytenko L, Verkhratsky A, Ögren SO, Nordberg A, Marutle A. Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic α7 Nicotinic Receptor Drugs. Neural Plast. 2015;2015:370432. doi: 10.1155/2015/370432. Epub 2015 Jul 15. PubMed PMID: 26257960; PubMed Central PMCID: PMC4518185.

2: Arias HR, De Rosa MJ, Bergé I, Feuerbach D, Bouzat C. Differential pharmacological activity of JN403 between α7 and muscle nicotinic acetylcholine receptors. Biochemistry. 2013 Nov 26;52(47):8480-8. doi: 10.1021/bi4012572. Epub 2013 Nov 11. PubMed PMID: 24164482.

3: Chen SG, Gu RX, Dai H, Wei DQ. Virtual screening for alpha7 nicotinic acetylcholine receptor for treatment of Alzheimer's disease. J Mol Graph Model. 2013 Feb;39:98-107. doi: 10.1016/j.jmgm.2012.11.008. Epub 2012 Nov 29. PubMed PMID: 23261879.

4: Ni R, Marutle A, Nordberg A. Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain. J Alzheimers Dis. 2013;33(3):841-51. doi: 10.3233/JAD-2012-121447. PubMed PMID: 23042213.

5: Lilja AM, Porras O, Storelli E, Nordberg A, Marutle A. Functional interactions of fibrillar and oligomeric amyloid-β with alpha7 nicotinic receptors in Alzheimer's disease. J Alzheimers Dis. 2011;23(2):335-47. doi: 10.3233/JAD-2010-101242. PubMed PMID: 21116052.

6: Arias HR, Gu RX, Feuerbach D, Wei DQ. Different interaction between the agonist JN403 and the competitive antagonist methyllycaconitine with the human alpha7 nicotinic acetylcholine receptor. Biochemistry. 2010 May 18;49(19):4169-80. doi: 10.1021/bi901999v. PubMed PMID: 20377277.

7: Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K, Hoyer D. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology. 2009 Jan;56(1):254-63. doi: 10.1016/j.neuropharm.2008.08.025. Epub 2008 Aug 28. PubMed PMID: 18793655.

8: Feuerbach D, Nozulak J, Lingenhoehl K, McAllister K, Hoyer D. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist. Neurosci Lett. 2007 Apr 6;416(1):61-5. Epub 2007 Jan 25. PubMed PMID: 17314009.